Amneal Pharmaceuticals (AMRX) investor relations material

Executive summary

• The proxy filing seeks shareholder approval for Amneal's acquisition of 100% of Kashiv BioSciences, LLC, including the issuance of 28,942,108 shares of Class A common stock and $375 million in cash, plus contingent milestone and royalty payments up to $350 million and 25% of certain gross profits over 12 years.

• The transaction is structured to expand Amneal's biosimilars platform, diversify growth, and leverage Kashiv's R&D and manufacturing capabilities, with anticipated financial and strategic benefits.

• The deal is subject to regulatory approvals (HSR Act, Indian law), shareholder votes, and other customary closing conditions, with expected completion in the second half of 2026.

Voting matters and shareholder proposals

• Shareholders are asked to vote on: (1) approval of the purchase agreement and transaction, (2) approval of the stock issuance, and (3) approval to adjourn the meeting if necessary.

• Approval of the transaction proposal requires a majority of votes cast by disinterested stockholders; the stock issuance proposal requires a majority of all votes cast.

• Both proposals must pass for the transaction to proceed; failure of either results in no acquisition.

Board of directors and corporate governance

• The transaction was negotiated and approved by an independent Conflicts Committee and recommended by the board, with certain directors recused due to conflicts.

• Restrictive covenants and amendments to the stockholders agreement are included to clarify governance and group definitions post-transaction.